Lead Healthcare.AI Completes Tens of Millions RMB Pre-A Financing Round, Accelerating Development with Robust Product Portfolio

VCBeat Latest News,Lead Healthcare Technology (Guangzhou) Co., Ltd. (hereinafter referred to as “Lead Healthcare”) has achieved another significant milestone in its development history by completing a Pre-A financing round worth tens of millions of yuan! This round was led by a globally leading hard-tech investment institution, with participation from Huameng Investment and Rongxinneng Investment. WinX Capital served as the exclusive financial advisor. This marks another major boost in capital for the company, following its nearly 100 million yuan angel financing round completed in early 2025, and will provide strong momentum for team building, product research and development, and market expansion.

Since its launch and operation in March 2024, Lead Healthcare.AI has achieved rapid and steady development in team building, product R&D, and market expansion:We have established a fully integrated, industrialized multidisciplinary team of over 100 members, with R&D personnel accounting for more than 60%. The team comprises top-tier talent across numerous specialized fields, including AI, optics, mechanics, electronics, computing, software, chips, biology, chemistry, environmental science, and materials science. Focusing on the cell industry chain, we have comprehensively deployed core technologies, components, and system-level solutions.Successfully launched over 10 high-end AI-powered life science instrument products and services, including an AI large model for intelligent cell recognition, a high-throughput AI imaging flow cytometer, a high-throughput single B-cell screening system, a high-throughput microbial screening system, a high-throughput microfluidic droplet generator, a fully automated protein purification system, an AI-based cell/organoid imaging analysis system, an organoid drug screening system, a fully automated stem cell culture and preparation system, a fully automated immune cell culture and preparation system, active single-cell sequencing systems/spatial transcriptomics and other single-cell multi-omics platforms, as well as microfluidic system modules (such as high-speed cameras, microfluidic micropumps/microvalves, and 96-channel positive pressure modules). Approximately 80% of the core technologies, components, and modular platforms are shared across these products. In the fields of life science instruments and bio-manufacturing equipment, we have established an efficient product development model characterized by “pre-researching one generation, developing one generation, and mass-producing one generation.” This has enabled us to form systematic, series-level product solutions integrating “AI + Life Science Instruments + High-End Medical Devices + Biopharmaceutical Equipment + Bio-manufacturing Equipment.” Looking ahead, we will continue to introduce more competitive product solutions, such as virtual cell AI large models and high-throughput AI drug screening systems. These initiatives aim to provide large-scale, high-quality, multi-modal data production tools and infrastructure for the “AI for Science” domain, leveraging AI-driven systems to accelerate development in life sciences, clinical diagnostics, biomedicine, and bio-manufacturing.

Lead Healthcare.AI actively implements the strategic direction of China’s 15th Five-Year Plan, driving decisive breakthroughs in key core technologies within priority areas such as high-end instrumentation and biomanufacturing. By deeply integrating artificial intelligence (AI) with life science instruments, high-end medical devices, and intelligent biomanufacturing equipment, the company has effectively addressed longstanding pain points in traditional life sciences and biomanufacturing—including low efficiency, high costs, and poor consistency—thereby enhancing efficiency, reducing costs, and improving quality and performance.

Lead Healthcare.AI's New Product Launch at the "2025 National Annual Academic Conference of the Chinese Society for Cell Biology" in April 2025

 Lead Healthcare.AI’s Launched Product Solutions

Lead Healthcare.AI has completed the construction of a pilot-scale platform for AI-enabled scientific instruments and bio-intelligent manufacturing equipment, featuring an AI scientific instrument innovation laboratory, a biochemical reagent innovation laboratory, a microfluidic chip innovation laboratory, and a GMP-compliant cell and gene therapy laboratory, spanning thousands of square meters. This infrastructure lays a solid foundation for large-scale mass production and delivery. The company has rapidly and steadily advanced the industrialization of its technological achievements, achieving simultaneous realization of both technical and market value.

Lead Healthcare.AI AI + Scientific Instruments and Bio-manufacturing Equipment Pilot Platform

Lead Healthcare.AI has also achieved remarkable results in commercial business development and sales. Within just over a year of its launch, the company has secured contract orders worth tens of millions of yuan from nearly 100 leading benchmark clients. Its customer base extensively covers top-tier universities and research institutions, premier Grade A tertiary hospitals, and leading biopharmaceutical companies in the industry.Among them, top-tier universities and research institutions include: Guangzhou Laboratory, Fudan University, Shanghai Jiao Tong University, Huazhong University of Science and Technology, Wuhan University, South China University of Technology, and the Chinese Academy of Sciences; leading Grade A tertiary hospitals and National Medical Centers include: West China Hospital of Sichuan University, Zhongshan Hospital Affiliated to Fudan University, Tongji Medical College of Huazhong University of Science and Technology, Peking University Sixth Hospital, Guangdong Provincial People's Hospital, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou First Municipal People's Hospital, The Third Affiliated Hospital of Sun Yat-sen University, and Chongqing General Hospital; among listed biopharmaceutical companies are GenScript Biotech and Kangwei Century.

Since its inception, Lead Healthcare.AI has consistently positioned intellectual property strategy as a core component of its development plan, leveraging technological innovation to build core competitive barriers. To date,Lead Healthcare.AI has independently filed over 110 patent applications, with invention patents and PCT international patents accounting for approximately 50%. The company has been granted more than 20 patents of various types and holds over 30 software copyrights.This series of intellectual property achievements covers key areas such as the R&D of core company products and breakthroughs in critical technologies, not only demonstrating the company’s strong independent R&D capabilities but also providing solid legal protection for the market competitiveness of its products. In April 2025, Lead Healthcare.AI was successfully selected as one of the first batch of excellent cases for patent transformation and application by the China National Intellectual Property Administration (CNIPA) in 2025. It was the only case selected from Guangdong Province among just 20 entities nationwide, and the sole representative from the scientific instruments and bio-manufacturing sectors. This achievement provides an innovative model for the industrialization of technological achievements and the transformation and application of patents in China’s high-end instrument and bio-manufacturing fields.

Lead Healthcare.AI Selected as One of the First Batch of Excellent Cases for Patent Conversion and Application by the China National Intellectual Property Administration in 2025

Meanwhile, Lead Healthcare.AI actively participates in standard-setting as an industry participant and co-developer of standards, promoting the standardized and high-quality development of the industry. Currently,Lead Healthcare.AI has cumulatively participated in the formulation of 26 various standards, including 7 national standards and 19 group standards.(Led the development of three group standards: Specifications for the Construction and Operation of Pilot-Scale Platforms in Biomanufacturing—Part 3: Cell Therapy Products; Technical Specifications for Imaging Flow Cytometry; and Image Analysis Systems for Flow Cytometers.) By deeply participating in the formulation of these standards, the company has translated its technological advantages and innovative practices into industry-wide consensus. This has not only enhanced the company’s influence within the sector but also facilitated the transformation and upgrading of the life sciences field from manual, workshop-based models to automated and intelligent systems.

With its outstanding innovation achievements and comprehensive strength, Lead Healthcare.AI has won numerous prestigious industry honors and qualifications in the more than one year since its opening and operation, becoming a rapidly developing industry benchmark enterprise in the field of life science instruments and biomanufacturing equipment:Successfully recognized as a National High-Tech Enterprise; won first place (First Prize) in the Growth Group of the Cell and Gene Therapy Track at the Guangzhou Science and Technology Innovation and Entrepreneurship Competition; won first place (First Prize) in the Entrepreneurship Group of the 9th “Maker Guangdong” Competition; won fifth place nationally (Third Prize) in the Entrepreneurship Group of the 10th “Maker China” Competition, being the only representative among the national top 10 in the fields of high-end instruments, biomanufacturing, biopharmaceuticals, and medical devices; won the Gold Award at the 2025 Greater Bay Area High-Value Intellectual Property Cultivation and Layout Competition; selected for the Ministry of Industry and Information Technology’s Typical AI Application Scenarios for SMEs and included in Guangzhou’s “AI+” Typical Cases, achieving dual recognition through authoritative certifications at both national and municipal levels.This series of honors and qualifications fully attests to the recognition by government authorities and the industry of the Company’s innovation capabilities and entrepreneurial potential, and stands as a testament to the diligent efforts of the Company’s team.

Lead Healthcare.AI won the First Prize in the Entrepreneurship Category of the 9th “Maker Guangdong” Competition, the Third Prize in the Entrepreneurship Category of the 10th “Maker China” Competition, and the First Prize in the Guangzhou Science and Technology Innovation and Entrepreneurship Competition, and was selected as a typical case of “AI+” by the Ministry of Industry and Information Technology and Guangzhou Municipality.

The lead investor in the Pre-A round stated: “Lead Healthcare.AI has demonstrated exceptional technological innovation capabilities and industrialization prowess in the fields of AI-driven life science instruments and biomanufacturing equipment. Its core team possesses deep expertise in multidisciplinary integration, aligning with the strategic direction of China’s 15th Five-Year Plan and industry trends encompassing ‘AI Plus,’ high-end instrumentation, life sciences, biopharmaceuticals, healthcare, and biomanufacturing. We are highly optimistic about Lead Healthcare.AI’s growth prospects. Our lead investment in this Pre-A financing round represents not only capital support but also a commitment to providing comprehensive empowerment in the future. We aim to accelerate technological innovation, product iteration, global expansion of Chinese technology, and international market development, jointly working to establish Lead Healthcare.AI as a global leader in technological innovation within the AI life science instruments and biomanufacturing equipment sectors.”

Zhang Feng, Founder and CEO of Lead Healthcare.AI, stated, “We are deeply grateful for the trust and support from all our investor partners. Against the backdrop of sustained capital market investment in hard technology, the completion of this Pre-A financing round not only recognizes our past achievements but also reflects high expectations for our future potential. Lead Healthcare.AI will primarily allocate the funds from this round to product R&D, capacity expansion, and market development. Moving forward, we will continue to deepen the integrated innovation of serialized, system-level product solutions across AI, life science instruments, high-end medical devices, biopharmaceutical equipment, and bio-manufacturing equipment. We aim to overcome critical bottlenecks in the high-end instrumentation sector, promote technological self-reliance in AI-driven life science instruments and intelligent bio-manufacturing equipment, and provide new-quality productive force solutions that enhance efficiency and reduce costs for life sciences, clinical diagnostics, biopharmaceuticals, and bio-manufacturing, thereby contributing to human health and longevity!”

From nurturing the “seeds of entrepreneurship in microfluidic chips, medical devices, and scientific instruments” through a National Natural Science Foundation of China project incubation application in 2008, to building a fully integrated, industrialization-focused team of over 100 professionals with multidisciplinary expertise; from joining the early stages of three startups—United Imaging Healthcare, DeepGlint, and UIS Robotics—in 2011 and gaining nine years of entrepreneurial experience, to joining Huawei in 2020 for three years of intensive practical training in DSTE strategic planning, IPD product development processes, and team organizational construction, before founding Lead Healthcare.AI in 2023; from drafting business plans to securing nearly RMB 100 million in angel financing and tens of millions in Pre-A financing; from being unknown and overlooked to emerging as a promising player and earning the favor and support of leading venture capital experts and top-tier investment institutions; from developing multiple principle prototypes and achieving patented scientific research outcomes at Guangzhou Laboratory to offering more than 10 serialized product solutions and services; from numerous innovative ideas to filing and laying out over 110 patents and participating in the formulation of more than 20 various standards; from pursuing a PhD at ETH Zurich in Switzerland to returning to China after studying abroad and then expanding globally with technology exports; and from strategic planning to strategic execution and implementation. The journey of Lead Healthcare.AI from 0 to 1 has spanned over a decade of meticulous accumulation and steadfast commitment, with every step taken firmly and steadily. We are deeply grateful to our benefactors and partners for their strong support, timely assistance, and win-win collaboration! The successful completion of this Pre-A financing round marks a new starting point for the vigorous development of Lead Healthcare.AI. In the future, Lead Healthcare.AI will continue to uphold its development philosophy of market leadership, innovation-driven growth, win-win cooperation, and mutual achievement. We will continuously increase R&D investment, improve our product portfolio, expand market channels, enhance core competitiveness, and serve more high-quality customers.

With strong winds propelling us on a long journey, we set sail again with heavy responsibilities. We sincerely thank all investment institutions, partners, industry colleagues, and members of society for their trust and support in Lead Healthcare.AI! Living up to your expectations, we will forge ahead with determination and contribute greater strength to promoting high-quality development in AI, life sciences, medical devices, biopharmaceuticals, biomanufacturing, and related fields. Let us join hands to create a brighter future together!

Lead Healthcare Technology (Guangzhou) Co., Ltd. (English name: Lead Healthcare.AI) is a hard-tech startup commercializing scientific and technological achievements from Guangzhou Laboratory. It independently develops AI-driven life science instruments and bio-manufacturing equipment, along with supporting AI algorithm systems, biochips, reagents and consumables, and technology services, and holds independent intellectual property rights.

The founding team is led by CEO Zhang Feng, former R&D Director at Huawei, medical device technical expert at United Imaging Healthcare, and serial entrepreneur, and CTO Cao Xiaobao, a scholar under the National Major Talent Program (Youth), researcher at Guangzhou Laboratory, and PhD/Postdoctoral Fellow/Senior Scientist at ETH Zurich. The team comprises outstanding PhDs and Masters graduates from leading domestic and international institutions such as ETH Zurich, Harvard University, the University of Cambridge, and the National University of Singapore. It also brings together industry elites from top-tier enterprises in artificial intelligence, life science instruments, medical devices, biopharmaceuticals, and biomanufacturing. With years of deep expertise in microfluidic chips, life sciences, biopharmaceuticals, medical devices, robotic automation, and AI, the team possesses extensive experience across the industrial chain, including technical research, innovation incubation, product development, clinical translation, and market promotion at prestigious universities and leading companies globally.Lead Healthcare.AI is a deep-tech company dedicated to providing automated, intelligent, and system-level solutions for the life science instrumentation and biomanufacturing equipment industries. It aims to enhance efficiency and reduce costs in fields such as biopharmaceuticals (including antibody drugs and cell and gene therapies) for tumor/cancer treatment and anti-aging, life science research, medical devices, and biomanufacturing. Upholding its vision of “contributing to human health and longevity,” its mission of “great heroes serve the country and the people; Lead Healthcare.AI promotes well-being and longevity,” and its values of “mutual achievement, win-win cooperation, successful outcomes with satisfied teams, and inclusiveness,” Lead Healthcare.AI remains committed to its original aspirations. The company strives to advance the industrialization of scientific and technological achievements, give back to scientific research, foster win-win cooperation with upstream and downstream partners in the industrial chain, tackle critical bottlenecks in AI-driven life science instruments and biomanufacturing equipment, and ultimately contribute to human health and longevity!